PharmGKB summary: voriconazole pathway, pharmacokinetics

Pharmacogenet Genomics. 2017 May;27(5):201-209. doi: 10.1097/FPC.0000000000000276.

Authors

Julia M Barbarino¹, Aniwaa Owusu Obeng, Teri E Klein, Russ B Altman

Affiliation

¹ Departments of aBiomedical Data Science bBioengineering, Stanford University, Stanford, California cIcahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine dDepartment of Medicine, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai eDepartment of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antifungal Agents / pharmacokinetics
Antifungal Agents / therapeutic use*
Aspergillus / drug effects
Aspergillus / pathogenicity
Candida / drug effects
Candida / pathogenicity
Fusarium / drug effects
Fusarium / pathogenicity
Humans
Mycoses / drug therapy*
Mycoses / genetics
Mycoses / microbiology
Pharmacogenetics*
Scedosporium / drug effects
Scedosporium / pathogenicity
Voriconazole / pharmacokinetics
Voriconazole / therapeutic use*

Substances

Antifungal Agents
Voriconazole

Grants and funding